NYSE MKTHealth CareMedical - Care FacilitiesSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage credit facilities to support acquisitions without overleveraging | Management is disciplined with capital, using credit to fund growth. | Intact | Credit usage exceeds $530 million without clear acquisition benefit | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 material events in 2026 including July and May filings. NHC drew down $530M in credit facilities to fund acquisitions and increased revolving credit from $50M to $75M. These actions show delivering on enhancing capital allocation strategies to support growth. Delivery assessment Oct 24, 2026 |
Maintain quarterly dividends at or above $0.64 per share | They keep paying steady dividends of $0.64 per share. | Intact | Dividend per share falls below $0.64 in any quarter | Dividend per share: $0.67 per share FY2026-Q2; GAAP. Published target: >= $0.64 per share quarterly. Target period is not explicitly aligned with this observation. Source published Aug 6, 20260.67 USD/share · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 97f4b862-56c2-4960-b04b-ef6034789d7e. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextMaintained dividend payments consistently over 3 quarters from 2025-Q4 to 2026-Q2, with dividends per share rising modestly from $0.64 to $0.67. This shows delivering on the commitment to maintain shareholder distributions. Delivery assessment Oct 24, 2026 |
Expand M&A activity in skilled nursing facilities | National Healthcare grows by buying skilled nursing facilities. | Improving | Acquisition activity falls below $560 million in 2026-Q3 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 disclosures including 2026-Q2 earnings and two 2026 press releases. Revenue grew 8.8% from $374.9M in 2025-Q2 to $408.0M in 2026-Q2, primarily driven by acquisitions. The $560M acquisition of 35 NHI facilities closed in Q3 2026, showing delivering progress on expanding M&A activity. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
NHC is an acquisition-led healthcare growth business with a durable premium versus peers. The long-term thesis is intact, though its signal has recently shifted from mildly favorable to mixed. Management is delivering on expansion and dividend priorities, while capital allocation progress is behind plan.
NHC trades at a 1.35 premium versus peers, reflecting a durable premium in the valuation. The expectations gap is 0.43, but confidence in that measure is medium. The evidence flags valuation as expensive, while saying the broader combination of expensive valuation, weak fundamentals, and turbulence is not present.
Recent financial performance is strong, and second-quarter revenue grew 8.8% year over year, primarily from acquisitions. The $560 million acquisition of 35 NHI facilities closed in the third quarter, while dividend payments have been maintained and raised modestly. Near term, consecutive earnings misses and a 42% estimated miss probability warrant attention, and a guidance cut would be a meaningful setback.
The multi-year case depends on NHC integrating acquisitions and sustaining growth while improving capital allocation execution. Near term, a guidance cut or further weakening in jobs data could weigh on the business outlook, while continued earnings strength and higher guidance from healthcare peers would support sector momentum. The evidence does not spell out further details on these scenarios.
Over the next 1 to 3 years, NHC’s thesis rests on acquisition-led growth and strong recent results, balanced against earnings misses, mixed signals, and behind-plan capital allocation. The current evidence supports an intact but execution-sensitive long-term thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.